GlassScriptPhysician profile
Rafael Sanchez Ponce
NPI 1669433223
$16,816.36
in general payments reported to CMS, 2019-2025
40 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,459 · 2020: $1,670 · 2021: $2,871 · 2022: $2,653 · 2023: $2,030 · 2024: $2,093 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,900 · Travel and Lodging: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,900.43 |
| Travel and Lodging | $263.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,283.29 | 2019-2025 | Lokelma, Farxiga |
| Medtronic, INC. | $2,086.28 | 2021-2024 | Venaseal, Reveal Linq |
| Boston Scientific Corporation | $1,471.26 | 2019-2025 | Varithena Administration Pack, Ekosonic, Watchman Flx |
| Janssen Pharmaceuticals, INC | $1,438.67 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,349.80 | 2019-2024 | Esprit, Jeti Peripheral Catheter, Confirm Rx |
| Abiomed | $1,001.31 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $991.78 | 2019-2025 | Lifevest |
| Amgen INC. | $719.59 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $694.27 | 2019-2025 | |
| Medtronic Vascular, INC. | $671.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.08 | 2019-2025 | Jardiance |
| Scpharmaceuticals INC. | $348.17 | 2024-2025 | |
| Pfizer INC. | $305.12 | 2019-2025 | |
| Astellas Pharma US INC | $298.08 | 2019-2022 | |
| Novo Nordisk INC | $280.11 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $272.04 | 2023-2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $249.76 | 2023-2024 | Inpefa |
| Janssen Scientific Affairs, LLC | $210.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $209.34 | 2021-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $204.13 | 2024-2025 | Onpattro |
| Angiodynamics, INC. | $175.79 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $161.61 | 2019-2024 | Eliquis |
| Shockwave Medical, INC | $143.18 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $115.96 | 2023-2024 | |
| Bridgebio Pharma, INC. | $85.96 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $84.09 | 2022-2025 | |
| Lilly USA, LLC | $71.70 | 2023-2025 | Mounjaro, Zepbound |
| Kestra Medical Technology Services, INC. | $56.18 | 2024-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $40.35 | 2020-2021 | |
| United Therapeutics Corporation | $30.88 | 2024 | Tyvaso |
| Cardiovascular Systems INC. | $30.12 | 2019-2020 | |
| Lundbeck LLC | $27.89 | 2019-2020 | |
| Edwards Lifesciences Corporation | $26.74 | 2020 | |
| Altathera Pharmaceuticals LLC | $24.39 | 2025 | Sotalol Hydrochloride |
| Amarin Pharma, INC. | $22.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2025 | Evkeeza |
| Biotronik INC. | $20.63 | 2025 | |
| Corcept Therapeutics | $19.31 | 2025 | Korlym |
| Kiniksa Pharmaceuticals International, Plc | $17.01 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Sanchez Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.